December 28, 2015 — IBA (Ion Beam Applications SA) has signed a contract with TMS (Tomorrow Medical Systems Co. Ltd.) for the installation of its single-room proton therapy system ProteusONE in Taiwan.
The contract signed in Taipei, includes the delivery of the ProteusONE equipment as well a long term service and maintenance agreement which together represents a value between EUR 30 to 35 million to IBA. This is the second contract signed with TMS for an installation of a proton therapy center in Taiwan. The first one was signed in 2013.
TMS is part of the CHC Healthcare Group (CHC), listed on the Taipei stock exchange. TMS operates radiotherapy services for a number of medical centers in Taiwan.
The ProteusONE system has been developed by IBA to allow more patients globally to access proton therapy. ProteusONE is a smaller, less expensive and faster to install proton therapy solution, encompassing the latest in proton therapy technologies, including Pencil Beam Scanning.
“CHC is very happy to partner with IBA to install a second ProteusONE system in Taiwan. ProteusONE allows patients to be treated with Intensity Modulated Proton Therapy using Pencil Beam Scanning Technology which will greatly benefit cancer patients in Taiwan,” said Pei-lin Lee, president of CHC Group.
The ProteusONE is the compact intensity modulated proton therapy (IMPT) solution from IBA. It benefits from the latest technologies developed with renowned clinical institutions. It is smaller, more affordable, easier to install and to operate. It is ultimately easier to finance, making this advanced radiation therapy modality available to more institutions and patients worldwide.
For more information: www.iba-worldwide.com
